Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Ltd, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Largactil 25mg/ml Solution for Injection.
| Pharmaceutical Form |
|---|
|
Sterile solution for injection. A clear, colourless or almost colourless solution. |
25mg/ml chlorpromazine hydrochloride.
For full list of excipients see section 6.1
| Active Ingredient | Description | |
|---|---|---|
| Chlorpromazine |
Chlorpromazine is a phenothiazine neuroleptic. Chlorpromazine has depressant actions on the Central Nervous System, with alpha-adrenergic blocking and anticholinergic activities. It has anti-emetic, anti-puritic, serotonin-blocking and weak anti-histamine properties and slight ganglion blocking activity. |
| List of Excipients |
|---|
|
Sodium sulphite anhydrous (E221) |
Largactil Injection 2.5% w/v is supplied in boxes containing 10 × 1 ml or 10 × 2 ml in glass ampoules.
Aventis Pharma Ltd, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0582
Date of First Authorisation: 24 April 2007
| Drug | Countries | |
|---|---|---|
| LARGACTIL | Australia, Estonia, Spain, France, Lithuania, Malta, New Zealand, Tunisia, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
